Nemaura Medical Inc.

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 01:27:40 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0542 ^USD	-4.39%		-35.55%	-75.25%

Apr. 10	Nemaura Medical Inc. Announces Board Changes	CI
Feb. 12	Nemaura Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell 3000E Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about Nemaura Medical Inc.

Nemaura Medical Inc. Announces Board Changes	Apr. 10	CI
Nemaura Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Nemaura Medical Inc.(OTCPK:NMRD) dropped from S&P TMI Index	Jan. 09	CI
Nemaura Medical Inc.(OTCPK:NMRD) dropped from NASDAQ Composite Index	Jan. 04	CI
Nemaura Medical Rolls Out Metabolic Health Program in UK	Nov. 14	MT
Nemaura Medical Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs	Nov. 14	CI
Nemaura Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Nemaura Medical Says Nasdaq Listing Standards Probably Won't Be Met by Deadline	23-09-14	MT
Nemaura Medical Announces Interim Results from Its Metabolic Health Program	23-09-13	CI
Nemaura Medical Says Interim Study Results Show Possibility of 24-Hour Glucose Meter Use	23-09-11	MT
Nemaura Medical Completes 100 Patient Study for Sugarbeat® 24-Hour Wear and Reports Interim Results	23-09-11	CI
HC Wainwright Adjusts Price Target on Nemaura Medical to $2.50 From $7, Maintains Buy Rating	23-08-21	MT
Nemaura Medical Secures Approval for sugarBEAT Glucose Sensor in Saudi Arabia	23-08-17	MT
Nemaura Medical Inc. Announces SFDA Approval of SugarBEAT®	23-08-17	CI
Nemaura Medical Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Nemaura Medical Receives $6.5 Million in New Funding	23-08-14	MT
EF Hutton Adjusts Price Target on Nemaura Medical to $4 From $6, Maintains Buy Rating	23-07-17	MT
Nemaura Medical Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-13	CI
Nemaura Medical Inc. Auditor Raises 'Going Concern' Doubt	23-07-12	CI
Nemaura Medical, Inc. Announces Next Commercialization Stage of Its proBEAT Sensor	23-06-27	CI
North American Morning Briefing : Stock Futures -2-	23-06-27	DJ
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell Microcap Growth Index	23-06-23	CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell Microcap Index	23-06-23	CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell 3000E Index	23-06-23	CI
Nemaura Medical Inc.(NasdaqCM:NMRD) dropped from Russell 3000E Growth Index	23-06-23	CI

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nemaura Medical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0542 USD

Average target price

1.5 USD

Spread / Average Target

+2,667.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEMAURA MEDICAL INC.	-75.25%	2.19M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution